Hirotaka Matsui

11PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematologyMedical microbiology not elsewhere classifiedMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 14, 2026
Response to comments on "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".

|Dec 28, 2025
Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan.

Hirotaka Matsui, Jun Takizawa, Kensuke Kojima

|Mar 16, 2024
Evaluation of the pathogenic potential of germline DDX41 variants in hematopoietic neoplasms using the ACMG/AMP guidelines.

Hirotaka Matsui, Makoto Hirata

|Jan 11, 2024
Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.

Hironori Arai, Hirotaka Matsui, SungGi Chi

|Dec 13, 2023
Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type.

Akira Nishimura, Kazuaki Yokoyama, Takuya Naruto

|Apr 18, 2023
Exposure to microbial products followed by loss of Tet2 promotes myelodysplastic syndrome via remodeling HSCs.

Takako Yokomizo-Nakano, Ai Hamashima, Sho Kubota

Pageof 2

Frequent Collaborators

3 joint publications

Akinori Kanai

2 joint publications

Satoru Shinriki

1 joint publications

Hideki Nakayama

1 joint publications

Akihiko Yokoyama